Estechpharma Co., Ltd. as one of the active venture companies, is remarkably growing at an average 50% more than previous year.It is due to not only concentrating on new technology-development with all our energies but also investing more than 10% of an annual turnover in R&D since its foundation in 1996 with company principal, the challenge and the creation.

Having short history, we synthesized more than 20kinds of API such as treatment of alcoholism, anti-inflammatory, anti-ulcerative, anti-thrombosis and anti-diabetic, which have been developed secondly or thirdly in the world and succeed the mass production of chiral-amino acid as key intermediates of new anti-viral compound and are proceeding it as regular producing.

Devoting all our energies into technology-development, we were selected as promising small and medium enterprise and awarded grand prize among small and medium enterprise and excellent technology-competitive, superior-technology enterprise from technology credit guarantee fund and technology-development model enterprise.

We acquired the approval of CEP (Certification of Suitability of Monographs of the European Pharmacopoeia) for Acamprosate Calcium from EDQM(European Directorate for the Quality of Medicines) in 2002, thanks to the effort of the executives and staffs of Estechpharma Co., Ltd. and close relationship with partners.

We will challenge for new technology-development and promote to world market continuously and do our best to be a leading company in the advanced pharmaceutical industry.

Thank you very much